Stephanie A Vuijk

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Intensive Care Unit

Patients With Inflammatory Bowel Disease

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Stephanie A Vuijk, Lissy de Ridder
Editorial: Infliximab induction therapy in paediatric Crohn's disease: A cost-effective strategy? Authors' reply. Alimentary pharmacology & therapeutics (2024)
Stephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick Ferry van Rheenen, Michiel P van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J Poley, Johanna C Escher, Lissy de Ridder
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease. Alimentary pharmacology & therapeutics (2024)
Stephanie A Vuijk, Lissy de Ridder
Editorial: Infliximab induction therapy in paediatric Crohn's disease - A cost-effective strategy? Authors' reply. Alimentary pharmacology & therapeutics 60 (1) (2024)
Stephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick Ferry van Rheenen, Michiel P van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J Poley, Johanna C Escher, Lissy de Ridder
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease. Alimentary pharmacology & therapeutics 59 (12) (2024)
Stephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick Ferry van Rheenen, Michiel P van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J Poley, Johanna C Escher, Lissy de Ridder
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease. Alimentary pharmacology & therapeutics 59 (12) (2024)
Stephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick Ferry van Rheenen, Michiel P van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J Poley, Johanna C Escher, Lissy de Ridder
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease. Alimentary pharmacology & therapeutics 59 (12) (2024)
Stephanie A Vuijk, Lissy de Ridder
Editorial: Infliximab induction therapy in paediatric Crohn's disease - A cost-effective strategy? Authors' reply. Alimentary pharmacology & therapeutics 60 (1) (2024)
Stephanie A Vuijk, Lissy de Ridder
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (5) (2023)
Stephanie A Vuijk, Lissy de Ridder
Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease. Alimentary pharmacology & therapeutics 56 (11-12) (2022)